The industry’s focus is on living organisms. The highly enforced standards make it an unique concern for business leaders. These attributes make the industry an ideal place to foster innovation. They have produced major breakthroughs in biofuels, crop yields, and life-saving pharmaceuticals.
Start-up biotech companies have many choices when it comes to revenue generation strategies, with most choosing either a technology partnering or an asset creation and out-licensing strategy. Technology partnering can generate more revenue and lower risk to the financials, whereas asset creation and outlicensing strategies can yield significantly higher returns. A growing number of biotechs at the early stages of research employ the hybrid approach, which combines these two approaches.
If you choose to go with a product-oriented strategy are more likely to achieve commercial success, if they are able to bring their pipelines to the right place, and then find a major pharmaceutical partner https://genotec-frankfurt.de/biotechnological-synthesis-of-remedies/ or a financier with deep pockets. This is expensive, however, and balancing opportunistic approaches to leveraging outside assets with the right research-based decisions regarding homegrown projects is key.
The “platform” model is an alternative option to generate revenue. It’s a less costly route than the product-oriented development, but it also involves significant risk. In this model, a biotech owns and develops its platform technology before joining with major pharma companies to create a portfolio drug discovery projects that specifically target diseases (i.e. disease x in biology y). Advinus Therapeutics, among others have embraced this method.
دیدگاهی یافت نشد